Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $666,986.55 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,455 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the sale, the executive vice president directly owned 20,221 shares of the company’s stock, valued at approximately $9,269,508.61. This trade represents a 6.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pushkal Garg also recently made the following trade(s):

• On Monday, August 18th, Pushkal Garg sold 1,396 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total transaction of $632,764.92.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $458.31 on Thursday. The company has a market cap of $60.08 billion, a price-to-earnings ratio of -185.55 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $466.31. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a 50 day moving average of $354.46 and a 200-day moving average of $294.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on ALNY shares. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. Finally, BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an “outperform” rating in a research report on Tuesday, June 24th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $405.33.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of ALNY. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals during the 1st quarter valued at $27,000. Park Square Financial Group LLC bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $28,000. Whipplewood Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $30,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.